阿片类药物使用障碍远程健康治疗的临床试验
阿片类药物使用障碍远程治疗随机临床试验
This trial will assess effects of enrollment in a comprehensive telehealth platform, RecoveryPad (RP), in adults with moderate or severe opioid use disorder.
研究概览
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名:Rebekah Heckmann, MD
- 电话号码:(203) 737-8335
- 邮箱:rebekah.heckmann@yale.edu
学习地点
-
-
Connecticut
-
New Haven、Connecticut、美国、06520
- 招聘中
- Yale University
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Can speak, read and write in English
- Provision of signed and dated informed consent form
- Screened positive for OUD, moderate or severe, based on the Diagnostic and Statistical Manual-5th Edition
- Have a working cell phone number and working device that can access a web browser and receive texts (i.e., smartphone, tablet or computer)
- Can provide a working email address OR be willing to create one
Exclusion Criteria:
- Current use of buprenorphine, methadone, or naltrexone for a substance use disorder
- Pregnancy
- Known current suicide risk based on participant self-report
- On parole or incarcerated at time of enrollment based on participant self-report
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:RecoveryPad platform
Participants randomized to RecoveryPad platform |
Telehealth platform to enhance motivation and engagement in treatment for OUD |
|
无干预:Treatment as usual
Treatment as usual: referrals to harm reduction and other community resources that are already being given to individuals in the various community and healthcare settings from which these participants are being recruited. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Attendance for MOUD
大体时间:Up to 30 days
|
Overall attendance will be measured by attendance (yes or no) at the first MOUD appointment within 30 days of enrollment. |
Up to 30 days
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Attendance for MOUD
大体时间:Up to 90 days
|
Overall attendance will be measured by attendance (yes or no) at the first MOUD appointment within 31 to 90 days of enrollment. |
Up to 90 days
|
|
Engagement with MOUD
大体时间:Up to 90 days
|
Engagement will be measured by demonstrated maintained attendance with MOUD treatment within 90 days of enrollment. |
Up to 90 days
|
|
Overdose Events at 30 Days
大体时间:Up to 30 days
|
A self-report of the number of subsequent overdose events within 30 days. |
Up to 30 days
|
|
Overdose Events at 90 Days
大体时间:Up to 90 days
|
A self-report of the number of subsequent overdose events within 90 days. |
Up to 90 days
|
合作者和调查者
调查人员
- 首席研究员:Rebekah Heckmann, MD、Yale University
- 首席研究员:Nasim Sabounchi, PhD、CUNY Graduate School of Public Health & Health Policy
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- 2000042683
- 1R61DA057675-01 (美国 NIH 拨款/合同)
- 2000041129 (其他标识符:Yale)
- 4R33DA057675-02 (美国 NIH 拨款/合同)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
In accordance with the HEAL Public Access and Data Sharing policy, de-identified IPD underlying the results reported in study-related publications will be shared. These will include participant-level data such as demographics/baseline characteristics, randomization results, and primary and secondary outcome measures.Direct identifiers will not be shared. Data will be de-identified using accepted standards.
IPD 共享时间框架
The de-identified IPD and relevant supporting documentation will be available no later than 12 months after completion of primary analyses and publication of the primary results, or within the period required by the HEAL Initiative data sharing policy. Data will remain available for a minimum of 3 years after the initial release date, subject to repository support and other policy requirements.
IPD 共享访问标准
All shared data and associated supporting documentation will be uploaded to the National Addiction and Health Data Archive Program.
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
在美国制造并从美国出口的产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.